Halozyme Therapeutics (NASDAQ:HALO) announced Friday the naming of Dr. Gregory I. Frost as its new chief executive, effective immediately, and a new head of science.
Frost is replacing Dr. Jonathan E. Lim, who has resigned to pursue other opportunities, according to the San Diego, Calif-based biopharmaceutical company.
Continue Reading Below
The biopharmaceutical company, which engages in the development and commercialization of products targeting extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, has also appointed H. Michael Shepard as its chief scientific officer.
Shepard originally joined the company as vice president of discovery research.
The board’s chairman, Kenneth J. Kelley, thanked Lim for his “excellent” work since joining the company in 2003 and noted he has been “instrumental in transforming Halozyme from a research company to one with a rich development pipeline and lucrative partnerships.”
Frost said he is passionate about the company’s future and has “confidence” the Halozyme team can achieve its goals.
The board has also accepted the resignation of Robert J. Little as vice president and chief commercial officer, effective immediately.